Lame duck session attempt at reform looks likely to fail given recent changes at the PTAB and growing public concern over drugs pricing in the US
iPhone maker says it believes it is in full compliance with injunctions issued ten days ago in Fuzhou. But the US company is coming in for sharp criticism in the Chinese press
Volume of new cases forecast to fall to under 4,000 for the first time since 2011 - and to well below levels for trademark and copyright suits
Doubling the hours allotted for the examination of each patent application would reduce the burden currently placed on rights owners in courts and at the PTAB, say professors in challenge to seminal Mark Lemley work
The battle over revenue share in licensing of multi-million dollar asset comes to light after Fortress brings infringement suit against Amazon
Despite proposed new statement, question remains over the extent to which Makan Delrahim’s FRAND policy will find approval with the man likely to be the next Attorney General
IAM uncovers the patents-in-suit, runs down the two sides’ validity wins and losses so far, and provides much more analysis of yesterday's shock preliminary injunction in the Intermediate People's Court of Fuzhou
After setback in Huawei suit, latest court cases show the state-funded Korean research institute is behind massive licensing programme
Boards and directors typically prioritise non-IP issues on the corporate agenda; however, legal requirements and market activities suggest that this might be a serious misstep.
Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions
There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.
The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative.
Life sciences companies in the United States are under increasing pressure. Campaigners for changes to the patent system are working to prevent what they see as abusive practices – and it looks as if they are winning the argument.
First application of the court’s SimpleAir standard led to a 45% slump in Invidior’s share price and could prove to be a boon for generics companies
TCL v Ericsson and Unwired Planet v Huawei send two very different messages to auto companies being approached by patent pools such as Avanci to take SEP licences, says Unified Patents' chief IP counsel Jonathan Stroud